pharmaphorum

FEBRUARY 23, 2022

The Japanese drugmaker will get access to Code Bio’s 3DNA non-viral genetic medicine delivery platform, initially for a liver-directed programme, and is also interested in deploying the technology for central nervous system disorders.

Gene Therapy 105

Gene Therapy Gene Gene Sequencing Immune Response 105

pharmaphorum

AUGUST 23, 2021

DNA vaccines work by delivering a genetically-engineered plasmid containing the DNA sequence encoding the desired antigen – in this case the SARS-CoV-2 spike protein – which is then taken up by cells. The company also says that it can update the vaccine very easily to deal with mutations in the virus.

DNA 98

DNA Vaccination Vaccine Genetic Engineering 98

pharmaphorum

NOVEMBER 30, 2020

“Our belief is that patients should understand the challenges associated with drug development and how those challenges impact them personally… It is emotionally challenging for patients who must put their faith in the hands of pharma companies”.

Gene Therapy 105

Gene Therapy Gene Antibody Clinical Trials 105

pharmaphorum

APRIL 26, 2022

Research into the area is being made possible through advancements in technology, such as being able to sequence genes at scale, allowing researchers to gain more detailed genetic data on the microbiome. Compelling advantages.

Containment 115

Containment Development Production Drugs 115

pharmaphorum

DECEMBER 21, 2020

It’s the first major partnership for Janux, which was set up in 2017, and could be the last to be organised by Merck’s R&D head Roger Perlmutter who is retiring from the big pharma company at the end of the year. billion deal with Seattle Genetics covering ADCs for breast cancer and other solid tumours.

Immune Response 59

Immune Response Sales Antibody Drugs 59

The Pharma Data

NOVEMBER 27, 2020

This week, another pharma company revealed a new technology device that can detect if a patient is infectious or not, while the Russian government published results of its Sputnik V vaccine, claiming it is more than 95 per cent efficient 42 days after the first dose.

Vaccination 52

Vaccination Vaccine Immune Response Marketing 52

Delveinsight

AUGUST 4, 2021

Similarly, genetics, immune response, and environmental factors also influence the occurrence of Neurological Conditions. The companies in the Parkinson’s Disease Therapeutics Market include Cortexyme, Cerevel Therapeutics, Amneal Pharmaceuticals, Pharma Two B, Cerevance, AbbVie, Theranexus, and others.

Marketing 98

Marketing Genetics Development Clinical Development 98